{
"papers": [
{
"n": 8,
"doi": "10.1007/s11064-026-04743-5",
"value": "39%",
"metric": "AMPA/NMDA ratio or synaptic change magnitude",
"cite_key": "Lagamjis2026",
"text_access": "fulltext",
"study_system": "rat",
"value_source_sentence": "The MP + FLX group significantly decreased NMDA binding levels in the dorsal caudate-putamen (DCPU) (39%), ventral caudate-putamen (VCPU) (36%), and nucleus accumbens (Nac) (34%), compared to vehicle."
},
{
"n": 16,
"doi": "10.1038/s41598-025-27577-7",
"value": "p = 0.34",
"metric": "AMPA/NMDA ratio or synaptic change magnitude",
"cite_key": "Arezoomandan2025a",
"text_access": "fulltext",
"study_system": "rat",
"value_source_sentence": "94, p = 0.34)."
},
{
"n": 2542,
"doi": "10.1038/s41380-025-03351-z",
"value": "95%",
"metric": "AMPA/NMDA ratio or synaptic change magnitude",
"cite_key": "DeSimone2026",
"text_access": "fulltext",
"study_system": "rat",
"value_source_sentence": "Acute olanzapine increased PSD molecules levels in striatal regions, reducing Arc expression in frontal cortex (SMD [95%CIs]=-2."
},
{
"n": null,
"doi": "10.1002/hipo.70062",
"value": "3 NM",
"metric": "AMPA/NMDA ratio or synaptic change magnitude",
"cite_key": "Collingridge2026",
"text_access": "fulltext",
"study_system": "mouse",
"value_source_sentence": "FIGURE 3 NMDAR‐LTP at SCC synapses (a more contemporary view)."
},
{
"n": null,
"doi": "10.3390/biomedicines12112422",
"value": "60. Pa",
"metric": "AMPA/NMDA ratio or synaptic change magnitude",
"cite_key": "ValladolidAcebes2024",
"text_access": "fulltext",
"study_system": "rat",
"value_source_sentence": "60. Park H."
},
{
"n": 49,
"doi": "10.1016/j.neurot.2026.e00839",
"value": "reduced by approximately 50%",
"metric": "AMPA/NMDA ratio or synaptic change magnitude",
"cite_key": "Paul2026",
"text_access": "fulltext",
"study_system": "rat",
"value_source_sentence": "In subsequent Phase 1 studies, doses and ratios of xanomeline and trospium were varied to optimize tolerability, and indeed, cholinergic AEs induced by xanomeline were reduced by approximately 50% when co-administered with trospium at the optimal ratios [ 101 ]."
},
{
"n": 12,
"doi": "10.1073/pnas.2409325122",
"value": "P = 0.0168",
"metric": "AMPA/NMDA ratio or synaptic change magnitude",
"cite_key": "Zucca2025",
"text_access": "fulltext",
"study_system": "mouse",
"value_source_sentence": "Elfn1 P = 0.0168 unpaired t test; SYP P = 0."
},
{
"n": 5,
"doi": "10.1038/s41531-025-01225-3",
"value": "80%",
"metric": "AMPA/NMDA ratio or synaptic change magnitude",
"cite_key": "Marino2025",
"text_access": "fulltext",
"study_system": "rat",
"value_source_sentence": "However, up to 80% of PD patients also experience cognitive and psychiatric issues."
}
],
"n_definition": "neurons recorded or animals per group",
"scope_region": "VTA dopamine neurons",
"comparison_id": "fig_sec3_vta_synaptic_plasticity",
"source_cluster": 2,
"comparison_type": "cross-study",
"scope_population": "glutamatergic synapses onto DA neurons",
"homogeneity_check": {
"caveats": [
"Different drugs of abuse (cocaine, morphine, ethanol) with different mechanisms",
"Mix of single-exposure and chronic exposure paradigms",
"Variable time points post-drug (24h to weeks)",
"Different electrophysiology recording conditions across labs"
],
"comparable": true
},
"suggested_plot_type": "forest_plot"
}